TagOcrelizumab

Psoriasis as a side effect of Ocrelizumab

I would be interested to know how many of you have experienced this with ocrelizumab (Ocrevus)? Is it a rare event or more or less uncommon (see Figure below). How to classify the likelihood of side effects Case 1 in this publication is a 40y old female with PPMS (Primary Progressive MS) who developed after the first half year of treatment, pustules, loss of skin, redness of her palms and soles...

MS futuroscope: Are you a quitter? 

Free your brain! Source: One of the burning matters in the MS community is how long we should advise pwMS to continue with immune suppressive therapies such as anti-CD20 monoclonal antibodies (mAb) (e.g. ocrelizumab).  Current situation:  At the moment, when you start with anti-CD20 there is no prefixed end date, implying you will continue years and potentially decades with the drug. As the...

A Tale of Two COVIDs – Delta and Omicron: What happens when you’re vulnerable & vaccinated – but still get the virus?

PART 1 – Rachel Horne tells her story It started in mid-November with a headache – a continual pain clamping down on my skull. Then came the tiredness. Reluctantly, I opened a lateral flow test – swabbed, squeezed and watched as two red lines quickly appeared on the test pad. Positive. I had COVID: the virus which for the past twenty months I’d done everything to dodge. I’d followed all the...

Infection risk secondary neutropenia with ocrelizumab

All drugs have a range of predictable side effects. In the case of immunosuppressants/immune depleting agents this is a low white cell count, which increases the risk of infection in the short- or long-term. Ocrelizumab is a monoclonal anti-B-cell (anti-CD20) treatment that specifically targets B-cells, but it may also have what we in the business call off target effects on other immune cells...

Guest-post from an ocrelizumaber

I uploaded a video to theMSguide.com a few days ago talking about my concerns as an ocrelizumab patient and how the potential lack of Covid vaccine response stood to impact my life. I am five full infusions into this DMT and the fact that it appears to severely impact the ability to generate a meaningful immune response after a Covid-19 jab is administered is no fault of anybody or anything. It...

Food for thought

The gastrointestinal tract (image taken from The Conversation) You may not think much of your gut, which in most peoples mind is simply one giant hosepipe from start to finish. But, this week after eating something quite oily, I was painfully made aware of my gut’s existence. The gut from an energy and metabolic point of view is a very important organ, and without it you would simply be a...

Vaccines and Ocrelizumab (VELOCE): Old swords, new swords, and how to avoid stab wounds!

As approximately 70% of our newly diagnosed people with MS go onto ocrelizumab (a CD20 and thus B cell-depleting monoclonal antibody), a study that helps us understand how ocrelizumab affects the potential to mount (protective) antibody responses to vaccines and new antigens is more than welcome. Especially, as we are all hoping for the COVID-19 vaccine to be under the Christmas tree.  B...

COVID-19 vaccine and ocrelizumab

The proof of the pudding is in the eating of it, not in the pudding or its concealed ingredients. Don’t take my word for it. From New York come two cases that were SARS-CoV-2 (COVID-19) antibody negative after developing COVID-19 while on ocrelizumab. Both cases were aged 39 and 42, within an age range that would be considered immune competent and therefore fully capable of forming an...

Neutropenia with ocrelizumab

If you buy into the mantra that a B cell therapy only works on B cells, then think again. Like a debutante three years shy of their first season, successful targeted therapies in the immune world are disappointing to say the least, and most definitely fall short of initial expectations. B cell ontogeny Ocrelizumab a humanized monoclonal antibody targeting CD 20 on the surface of B cells during...

JCV index and the effect of DMTs

JCV STRATIFY (anti-JCV antibody) test has been utilized for more than decade to de-risk natalizumab treatment and other DMTs for risk of PML (Progressive Multifocal Leukoencephalopathy). Cases of PML have occurred predominantly in natalizumab, but less commonly with fingolimod (Gilenya), dimethylfumerate (Tecfidera) and rituximab. A high JCV antibody index value indicates that the risk of...

Translate

Categories

Recent Posts

Recent Comments

Archives